#Emerging Players in US Acute Myeloid Leukemia Market | Explore Tumblr Posts and Blogs

kenresearch1 · 10 months

Text

The Transformative Growth of the US Acute Myeloid Leukemia Market

Buy Now

What is the Size of US Acute Myeloid Leukemia Industry?

US Acute Myeloid Leukemia Market is expected to grow at a CAGR of ~ % in 2022 and is expected to reach ~USD Mn by 2028. The US Acute Myeloid Leukemia market is the rapid advancement in precision medicine and targeted therapies. The emergence of innovative treatments tailored to the genetic and molecular characteristics of individual AML patients has transformed the treatment landscape. Targeted therapies, such as FLT3 and IDH inhibitors, capitalize on specific genetic mutations driving AML, resulting in higher response rates and improved outcomes compared to traditional approaches.

Precision medicine's ability to identify the most effective treatment for each patient not only enhances therapeutic efficacy but also reduces unnecessary treatments, mitigating side effects and improving overall quality of life. This paradigm shift is bolstered by technological progress in molecular profiling techniques like next-generation sequencing, allowing for accurate genetic profiling and treatment customization.

Furthermore, regulatory support and accelerated approval pathways for targeted therapies have expedited their availability to patients. Pharmaceutical companies' increasing investment in research and development of novel agents, along with collaborations between academia and industry, leads to grow this market even more.

Click here to Download a Sample Report

US Acute Myeloid Leukemia Market by treatment type

The market is segmented by Treatment type into Chemotherapy, Targeted Therapy, Hormone Therapy, Immunotherapy and Others. Targeted Therapy is the dominant segment in the US Acute Myeloid Leukemia market in 2022. Specialty Centers, dedicated to the diagnosis, treatment, and management of specific medical conditions like AML, offer a concentrated and specialized approach to patient care. Their dominance in the AML market is driven by their unique capabilities to provide comprehensive and tailored treatments that address the complex needs of AML patients.

US Acute Myeloid Leukemia Market by end -user industry

The market is segmented by End-User into Hospitals, Homecare, Specialty Centers, Pharmacies and Others. Among these, Specialty Centers are the dominant End-User in the US Acute Myeloid Leukemia market in 2022. Specialty centers have a higher level of expertise and experience in treating specific types of cancer, including acute leukemia. They typically have specialized medical professionals, including hematologists and oncologists, who are well-versed in the latest treatment protocols and research. These centers are equipped with state-of-the-art diagnostic and treatment facilities that are specifically tailored to the needs of leukemia patients. This can include advanced imaging technologies, specialized laboratories, and access to cutting-edge therapies.

Click here to Download a Custom Report

US Acute Myeloid Leukemia companies market by Region

The US Acute Myeloid Leukemia market is segmented by Region into North, South, East, West. The dominance region is North in the US Acute Myeloid Leukemia Market in 2022. the North region often benefits from a higher level of funding for medical research, including AML. Federal funding agencies, private foundations, and pharmaceutical companies frequently channel resources into institutions within this region, allowing for greater research capabilities and clinical trials infrastructure.

Competition Scenario in US Acute Myeloid Leukemia Market

The US acute myeloid leukemia market was characterized by the presence of several prominent pharmaceutical companies and biotechnology firms striving to establish their presence and gain a competitive edge.

Larger corporations, smaller biotechnology companies making significant contributions to the AML landscape. Companies like Agios Pharmaceuticals and Daiichi Sankyo were gaining attention for their novel therapies targeting AML-associated mutations. These players are often at the forefront of introducing precision medicine approaches to AML treatment, taking advantage of advancements in genetic profiling and molecular diagnostics.

The competition is further intensified by research collaborations and partnerships between pharmaceutical companies, academic institutions, and research organizations. These collaborations aimed to combine resources, expertise, and insights to accelerate the development of effective therapies.

What is the Expected Future Outlook for the Overall US Acute Myeloid Leukemia market?

The US Acute Myeloid Leukemia market was valued at USD ~Million in 2022 and is anticipated to reach USD ~ Million by the end of 2028, witnessing a CAGR of ~% during the forecast period 2022- 2028. Pharmaceutical companies have been actively researching and developing novel therapies for Acute Myeloid Leukemia, with a focus on improving patient outcomes and reducing the side effects associated with traditional treatments like chemotherapy. The approval of new drugs, such as FLT3 and IDH inhibitors, has offered fresh therapeutic avenues for specific subsets of Acute Myeloid Leukemia patients with genetic mutations.

The future outlook for the US Acute Myeloid Leukemia market is anticipated to be influenced by a combination of factors including advancements in treatment options, evolving regulatory landscapes, and a growing understanding of the molecular basis of Acute Myeloid Leukemia. The market has been witnessing a shift towards personalized medicine, with increasing emphasis on targeted therapies and precision medicine approaches.

Furthermore, the integration of innovative technologies like next-generation sequencing (NGS) has enhanced our understanding of Acute Myeloid Leukemia’s molecular complexities, allowing for better patient stratification and treatment selection. This trend toward molecular profiling and personalized treatment regimens is likely to continue shaping the market landscape.

However, challenges persist. Despite progress, Acute Myeloid Leukemia remains a difficult-to-treat disease with a high relapse rate. Overcoming drug resistance and developing effective strategies for patients who do not respond well to existing therapies remain critical areas of focus.

Additionally, the cost of novel therapies and access to these treatments could also impact their adoption and availability. The regulatory environment, including expedited pathways for drug approvals, continue to influence market dynamics.

0 notes

priteshwemarketresearch · 1 month

Text

Olutasidenib Market Research Trends Analysis by 2024-2034

Olutasidenib Market Introduction:

Olutasidenib is emerging as a pivotal drug in the oncology field, targeting cancers with specific genetic mutations. Developed to inhibit the mutant form of the isocitrate dehydrogenase 1 (IDH1) enzyme, olutasidenib offers a targeted approach for treating cancers driven by IDH1 mutations, particularly acute myeloid leukemia (AML).

Unlock your exclusive sample PDF now:

Market Trends

Increasing Adoption in Clinical Practice: Olutasidenib's clinical trials have shown promising results, particularly in treating acute myeloid leukemia (AML) and other hematologic malignancies. The drug's effectiveness in targeting IDH1 mutations has garnered interest from oncologists, leading to its gradual adoption in clinical settings. As more data becomes available, the use of olutasidenib is expected to become more widespread, further driving market growth.

Growing Pipeline of IDH1-Mutant Cancers: The olutasidenib market is benefiting from an expanding pipeline of IDH1-mutant cancers. Research is ongoing to evaluate the drug's efficacy in various cancer types beyond AML, including solid tumors. This broadening scope is likely to enhance market potential and create new opportunities for pharmaceutical companies.

Increasing Investment and Partnerships: Pharmaceutical companies are investing heavily in the development and commercialization of targeted therapies like olutasidenib. Strategic partnerships and collaborations are becoming more common as companies seek to leverage each other’s strengths in research, development, and market access. These alliances are crucial for accelerating the drug’s availability and expanding its reach.

Opportunities in the Olutasidenib Market

Expanding Indications: While olutasidenib is currently approved for specific indications, there is significant potential for expanding its use. Ongoing research is exploring its effectiveness in additional cancer types and stages. Successfully gaining approval for these new indications could substantially increase the drug's market share.

Global Market Expansion: As the drug continues to demonstrate its efficacy, there is a growing opportunity for global market expansion. Different regions may have varying rates of IDH1-mutant cancers, which could influence the drug's market dynamics. Companies that successfully navigate regulatory pathways in diverse markets will have a competitive advantage.

Personalized Medicine: The rise of personalized medicine is a key factor driving the olutasidenib market. With a focus on precision oncology, treatments are increasingly tailored to the genetic profiles of individual patients. Olutasidenib’s targeted approach aligns well with this trend, offering the potential for more effective and personalized cancer treatment.

Olutasidenib Market Segments

by Type

Generic Olutasidenib

Branded Olutasidenib

by Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Olutasidenib Market Key Market Players

AbbVie Inc.

Olutasidenib Industry: Regional Analysis

North America Market Forecast

With a Olutasidenib Market share of more than 47%, North America leads the global olutasidenib industry in terms of revenue generation. Because of its sophisticated healthcare system and large R&D expenditures, North America is one of the top markets for olutasidenib. Novel treatments are highly sought for due to the high incidence of acute myeloid leukemia (AML) and the large number of clinical studies carried out in the United States and Canada. Market potential is further enhanced by this region's established healthcare infrastructure and emphasis on innovative treatments.

European Market Data

Europe's market for olutasidenib is bolstered by its extensive clinical research endeavors and strong healthcare infrastructure. Demand is increased by the high cancer incidence rates and favorable regulatory regimes found in nations like Germany, France, and the UK. The potential for Olutasidenib's expansion in Europe is enhanced by the region's investment in cancer research and development, as well as the enhancement of patient access to innovative medicines.

Challenges and Considerations

High Development Costs: Developing and bringing a novel drug to market involves substantial investment. The costs associated with clinical trials, regulatory approvals, and market access can be significant. Companies must carefully manage these expenses to ensure a favorable return on investment.

Competition and Market Saturation: The oncology market is highly competitive, with numerous therapies targeting similar pathways. As more drugs enter the market, olutasidenib will need to demonstrate clear advantages in efficacy and safety to maintain its competitive edge.

Regulatory Hurdles: Navigating the regulatory landscape can be complex and time-consuming. Companies must adhere to rigorous standards to gain approval for new indications and international markets. Successfully overcoming these regulatory hurdles is essential for maximizing market potential.

Olutasidenib and Clinical Trials

Before its approval, Olutasidenib Market underwent rigorous clinical trials to evaluate its safety and efficacy. These studies demonstrated promising results in terms of:

Response Rate: A significant number of patients experienced complete or partial remission of their AML.

Survival: Patients treated with olutasidenib showed improved overall survival compared to standard treatment options.

Key benefits of olutasidenib include:

Targeted therapy: Specifically addresses the underlying genetic cause of AML in patients with the IDH1 mutation.

Oral administration: Convenient and patient-friendly compared to traditional intravenous chemotherapy.

Improved outcomes: Demonstrated effectiveness in clinical trials, leading to increased response rates and improved survival.

Future Outlook

The future of the olutasidenib market appears promising, with ongoing research and development efforts poised to enhance its therapeutic potential. As the drug continues to show efficacy in clinical trials and expands its indications, it is likely to become a cornerstone of treatment for IDH1-mutant cancers. Additionally, advancements in personalized medicine and global market expansion will further drive growth.

Conclusion,

Olutasidenib represents a significant advancement in targeted cancer therapy. Its market trajectory will be shaped by continued research, strategic partnerships, and the evolving landscape of oncology. For investors, healthcare professionals, and patients alike, the Olutasidenib Market offers a glimpse into the future of personalized and effective cancer treatment.

#healthcare #industry #analysis

0 notes

itssashasharma · 3 years

Text

Hemato Oncology Testing Market worth USD 4.0 billion : Increasing Incidence of Hematologic Cancer

According to the new market research report “Hemato Oncology Testing Market by Product & Services (Assay Kits, Services), Cancer (Leukemia (Acute Lymphoblastic, Acute Myeloid), Non-Hodgkin’s Lymphoma), Technology (PCR, NGS, IHC), End-User (Clinical Laboratories, Hospitals) – Global Forecast to 2024″, published by MarketsandMarkets™, the Hemato Oncology Testing Market is projected to reach USD 4.0 billion by 2024 from USD 2.0 billion in 2019, at a CAGR of 14.8%.

Browse in-depth TOC on “Hemato Oncology Testing Market“

77 – Tables

29 – Figures

116 – Pages

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=262472877

Growth in this market is driven mainly by the rising prevalence of lymphoma & myeloma cancers, growing focus on personalized medicine, and increasing collaborations for developing assays.

The services segment accounted for the largest share of the product & services segment in the Hemato Oncology Testing Market in 2018.

Based on product & services, the market is segmented into assay kits and services. In 2018, the services segment accounted for the largest share of the product & services segment in the Hemato Oncology Testing Market. The large share of this segment can be attributed to the rising prevalence of hematologic cancers and increasing aging population.

Availability of robust infrastructure and high-end equipment for conducting hemato oncology tests are the supporting factors for clinical laboratories segment

Based on end-user, the Hemato Oncology Testing Market has been segmented into four types, i.e., clinical laboratories, hospitals, academic & research institutes, and other end-users. Other end-users include CROs and pharmaceutical & biotechnological companies. Clinical laboratories accounted for the largest share of the market in 2018. This segment is expected to grow at the highest rate in the coming years. This is mainly due to the presence of advanced diagnostic equipment such as analyzers and the presence of skilled professionals to perform these tests.

North America accounted for the largest share of the Hemato Oncology Testing Market in 2018

North America accounted for the largest share of the Hemato Oncology Testing Market in 2018. The large share of this segment can primarily be attributed to the high incidences of hematologic cancer, aging population, awareness regarding advanced treatment methods, and the strong presence of industry players in the region. These trends are likely to drive market growth during the forecast period.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=262472877

Some of the leading players in the Hemato Oncology Testing Market include F. Hoffmann-La Roche Ltd. (Switzerland), Abbott Laboratories (US), Thermo Fisher Scientific, Inc. (US), QIAGEN N.V. (Germany), Bio-Rad Laboratories, Inc. (US), Illumina, Inc. (US), MolecularMD (Ireland), Invivoscribe, Inc. (US), Asuragen, Inc. (US), Adaptive Biotechnologies (US), ArcherDx, Inc. (US), and ARUP Laboratories Inc. (US).

Browse Adjacent Markets: Medical Devices Market Research Reports & Consulting

Browse Related Reports:

Molecular Diagnostics Market by Application (Infectious Disease (Hepatitis, HIV), Oncology, Genetic Testing), Technology (PCR, DNA Sequencing & NGS), End User (Hospital/Academic Laboratory), Product & Service (Reagent, Software) – Global Forecast to 2023

Companion Diagnostics Market by Indication (Breast cancer, NSCLC, Colorectal cancer, Neurological disorders, Infectious Diseases), Technology (PCR, IHC, NGS, ISH), End User (Pharmaceutical & Biopharmaceutical Companies, Reference Lab) – Global Forecast to 2022

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the “Growth Engagement Model – GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, “Knowledge Store” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact: Mr. Shelly Singh MarketsandMarkets™ INC. 630 Dundee Road Suite 430 Northbrook, IL 60062 USA: +1-888-600-6441 Email: [email protected] Research Insight: https://www.marketsandmarkets.com/ResearchInsight/hemato-oncology-testing-market.asp Visit Our Website: https://www.marketsandmarkets.com Content Source: https://www.marketsandmarkets.com/PressReleases/hemato-oncology-testing.asp

#Hemato Oncology Testing Market

0 notes

techsciresearch · 3 years

Text

Saudi Arabia Poultry Market to Witness Steady Growth till 2026 | TechSci Research

Strong economic growth and the growing food requirements is expected to drive the demand for Saudi Arabia Poultry market in the forecast period.

According to TechSci Research report, “Saudi Arabia Poultry Market By Type (Broiler, Eggs, Others) By Product Type (Raw, Chilled, Frozen) By Nature (Organic, Conventional) By Distribution Channel (Supermarkets/Hypermarkets, Traditional Stores, Specialized Stores, Online, Others), By region, Company Forecast & Opportunities, 2026”, The Saudi Arabia Poultry market is expected to witness steady growth in the forecast period. The rapid urbanization of the people to live in better conditions and search for employment opportunities is contributing to the growth of the poultry market and enhancing the demand for processed and unprocessed chicken and eggs.

Support of the leading authorities for the development of the poultry market in form of relaxation in income tax, direct subsidies for select food items, interest-free loans, and duty-free imports of raw materials. The leading authorities are providing support to the local manufacturers and taking significant measures to reduce the mortality rate of the bird. An increase in the preference of the consumers for low-fat and high-protein-containing food items is fostering the growing demand of the market. The development of the trade channel and the technological advancements to keep the freshness of the food items and aid in increasing the shelf life of the edible animal food items is fostering the growth of the poultry market.

The increase in the demand for frozen and chilled food items is influencing the demand for poultry-based products in the region. The high demand for the consumption of poultry-based products and the unavailability of quality animal-based edible items in the country and the need to import the animal-based food items are creating lucrative opportunities for the growth of the poultry market. The Saudi government is making heavy investments for the infrastructural development of the country in order to develop the retail and hospitality sector in the country. Under the Saudi Vision 2030, the development of the tourism industry to attract more tourists to the country for religious and other purposes, the government is aiming to develop the poultry sector to meet the growing food requirements.

The COVID-19 outbreak across the world which has been declared as a pandemic by World Health Organization has affected several countries adversely. Leading authorities of Saudi Arabia imposed lockdown restrictions and released a set of precautionary measures to contain the spread of novel coronavirus. The coronavirus pandemic hit the economic status of the country which negatively impacted the growth of the industry. Disruption in the supply chain was observed which adversely affected the supply of raw materials around the country.

However, the growing cost of the poultry feeds and strict quality checks and norms may hamper the Saudi Arabia Poultry market growth in the forecast period.

Browse XX Figures spread through XX Pages and an in-depth TOC on "Saudi Arabia Poultry Market”.

https://www.techsciresearch.com/report/saudi-arabia-poultry-market/7726.html

Saudi Arabia Poultry market is segmented into type, product type, nature, distribution channel, regional distribution, and company. Based on the type, the market can be divided into broiler, eggs, and others. The broiler segment is expected to witness growth in the next five years, 2022-2026. The rise in the demand for whole chicken and its parts and the increasing affordability of the consumers is fostering the growth of this segment. The Hajj pilgrimage attracts a lot of tourists in the country which is expected to fuel the demand and rapid development of the catering service market. The rise in the development of the construction industry and the liability of the company to provide three meals a day is contributing to the growth of the poultry market as the normal diet in Saudi Arabia includes the portion of animal meat or products.

Almarai Saudi Arabia, Al-Watania Poultry Company, Al-Fakeih Poultry, Al-Berri United Food Co. Ltd, Alwadi Poultry Farms Ltd, Co., Arabian Agricultural Services Company, Arabian Farms Dev.Co.Ltd., Alsalamah Almotatawera Co, BRF S.A, Bayle S.A., Cargill Incorporated, Cherkizovo Group are the leading players operating in Saudi Arabia Poultry market. Manufacturers are increasingly focusing on research and development process to fuel higher growth in the market. To meet evolving customer demand with respect to better efficiency and durability, several Poultry manufacturers are coming up with their technologically advanced offerings.

Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=7726

Customers can also request for 10% free customization on this report.

“Development of the online commerce channels to improve the reach of products and brand image, the market players are investing huge amounts. The offering of attractive discounts and the facility for home delivery and online payment gateways ate contributing to the growth of the market. The market players are adopting advanced technologies such as 3-D imaging systems to determine the way for optimal cuts and minimize the per-unit cost for poultry processing. The use of latest technologies and the development of efficient distribution channels is expected to propel the growth of the Poultry market till 2026” said Mr. Karan Chechi, Research Director with TechSci Research, a global research-based management consulting firm.

“Saudi Arabia Poultry Market By Type (Broiler, Eggs, Others) By Product Type (Raw, Chilled, Frozen) By Nature (Organic, Conventional) By Distribution Channel (Supermarkets/Hypermarkets, Traditional Stores, Specialized Stores, Online, Others), By region, Company Forecast & Opportunities, 2026” has evaluated the future growth potential of Saudi Arabia Poultry market and provided statistics & information on market size, shares, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in the of Saudi Arabia Poultry market.

Browse Related Reports:

Global Organic Food Market By Product Type (Organic Meat, Poultry & Dairy; Organic Fruits & Vegetables; Organic Processed Food; Organic Bread & Bakery; Organic Beverages; Organic Processed Food and Others), By Distribution Channel Type (Hypermarket/Supermarket, Speciality Stores, Departmental Stores, Online and Others (Spices, Pulses, Cereals &Food Grains etc.), By Region, Competition, Forecast Opportunities, 2026

https://www.techsciresearch.com/report/organic-food-market/4401.html

Vietnam Frozen Food Market By Category, ((Ready-to-Eat, Ready-to-Cook & Others (Raw Meat, Raw Vegetables, Raw Fruit, etc.)), By Product Type (Frozen Meat, Poultry, & Seafood, Frozen Snacks, Frozen Fruits & Vegetables, Frozen Desserts, Frozen Cooked Ready Meals, & Others), By Distribution Channel (Departmental Stores, Specialty Stores, Supermarket/Hypermarket, Online & Others (Convenience Stores, Direct Sales, etc.)), By Region, Competition, Forecast Opportunities, 2026F

https://www.techsciresearch.com/report/vietnam-frozen-food-market/2942.html

Global Leukemia Therapeutics Market By Type (Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphocytic Leukemia, Others), By Gender (Male, Female), By Age Groups (0-15, 15-30, 30-50, 50+), By Diagnosis (Blood Test, Biopsy, Physical Exam, Imaging), By Treatment (Chemotherapy, Stem Cell Transplantation, Immunotherapy, Targeted Therapy, Others), By Drugs (Tyrosine Kinase Inhibitors, Antimetabolites, Hormones (Corticosteroids), Monoclonal Antibodies, Others), By Route of Administration (Oral, Parenteral), By Region, Competition Forecast & Opportunities, 2026

https://www.techsciresearch.com/report/leukemia-therapeutics-market/4534.html

Global Outpatient Hospital Services Market By Services (Treatment Services, Diagnostic Tests, Minor Surgical Procedures, Others) By Type (Emergency Department, Urgent Care Centers, Primary Care Clinics, Specialized Outpatient Clinics, Others) By Region, Competition Forecast & Opportunities, 2026

https://www.techsciresearch.com/report/outpatient-hospital-services-market/7732.html

Saudi Arabia Seafood Market By Product (Fish, Shrimp, Crab, Lobster, Others) By Type (Raw, Frozen, Processed) By Application (Retail, Institution Sales and Food Service) By Distribution Channel (Supermarket/Hypermarket, Departmental Stores, Specialized Stores, Online, Others), Company Forecast & Opportunities, 2026

https://www.techsciresearch.com/report/saudi-arabia-seafood-market/7727.html

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: [email protected]

Website: https://www.techsciresearch.com/

For More Market Research Blogs Visit: https://techsciblog.com/

#TechSci #Market Research Reports #Saudi Arabia Poultry Market #Poultry Market #Saudi Arabia Poultry Market Size #Saudi Arabia Poultry Market Forecast

0 notes

techscimarketresearch · 3 years

Text

Saudi Arabia Poultry Market to Witness Steady Growth till 2026 | TechSci Research

Strong economic growth and the growing food requirements is expected to drive the demand for Saudi Arabia Poultry market in the forecast period.

However, the growing cost of the poultry feeds and strict quality checks and norms may hamper the Saudi Arabia Poultry market growth in the forecast period.

Browse XX Figures spread through XX Pages and an in-depth TOC on "Saudi Arabia Poultry Market”.

https://www.techsciresearch.com/report/saudi-arabia-poultry-market/7726.html

Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=7726

Customers can also request for 10% free customization on this report.

Browse Related Reports:

https://www.techsciresearch.com/report/organic-food-market/4401.html

https://www.techsciresearch.com/report/vietnam-frozen-food-market/2942.html

https://www.techsciresearch.com/report/leukemia-therapeutics-market/4534.html

https://www.techsciresearch.com/report/outpatient-hospital-services-market/7732.html

https://www.techsciresearch.com/report/saudi-arabia-seafood-market/7727.html

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: [email protected]

Website: https://www.techsciresearch.com/

For More Market Research Blogs Visit: https://techsciblog.com/

#TechSci #Market Research Reports #Saudi Arabia Poultry Market #Poultry Market #Saudi Arabia Poultry Market Size #Saudi Arabia Poultry Market Forecast

0 notes

jesse-pinkman123 · 3 years

Text

Theranostics Market Size Share Trends Forecast Opportunity Analysis 2026

Global Theranostics Market Drivers:-

Development of novel companion diagnostic tests to be used with available treatment options is expected to boost the global Theranostics Market growth over the forecast period. Leading manufacturers are engaged in introduction of novel companion diagnostic tests in market. For instance, Illumina, Inc. announced launch of the U.S. Food & Drug Administration (FDA) approved extended RAS panel for identification of patients eligible for treatment of metastatic colorectal cancer with Vectibix (panitumumab) in 2017.

Increasing adoption of companion diagnostic tests by laboratories is further expected to foster global theranostics market growth over the forecast period. BloodCenter of Wisconsin's Diagnostic Laboratories started offering Abbott RealTime IDH1 assay for patients with acute myeloid leukemia (AML) in July 2018. Moreover, Cancer Genetics, Inc. started offering FDA approved companion diagnostic Thermo Fisher Scientific's Oncomine Dx Target - the first Next-Generation Sequencing (NGS)-based Companion Diagnostic (CDx) test in 2017. Laboratory Corporation of America Holdings launched OmniSeq Advance in partnership with OmniSeq for tumor cancers in June 2018.

Partnerships and collaborations by leading manufacturers to develop innovative companion diagnostics is expected to foster global theranostics market growth over the forecast period. For instance, Foundation Medicine, Inc. and Pfizer, Inc. entered into a partnership for development, regulatory support, and commercialization of companion diagnostics (CDx) in January 2018. Moreover, Qiagen, Inc., and Freenome partnered in June 2018, to accelerate the development and commercialization of Next-Generation Sequencing (NGS) tests to enable precision medicine in cancer treatment.

Pierre Fabre and Roche have been working on development of a robust prototype immunohistochemistry assay as a future companion diagnostic test for W0101 (the drug candidate which they are developing together) and extended this collaboration in May 2018. Abbott Laboratories, Inc. collaborated with Celgene Corporation, and Agios Pharmaceuticals, to develop diagnostic tests on Abbott’s m2000 RealTime system that identifies certain genomic mutations associated with acute myeloid leukemia (AML) in 2016. These factors are expected to support global theranostics market growth over the forecast period.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/2043

Theranostics involves combination of targeted diagnostic tests with targeted therapy. It is also known as companion diagnostics, integrated medicine, Dx/Rx partnering, and pharmacodiagnostics. Implementation of theranostics into the patient care plan (in case of selected diseases for which diagnostic tests are available along with respective therapy) may turn into personalized therapy, which could further improve medical outcomes.

Theranostics include use of specific diagnostic test, which shows a particular molecular target on a tumor or any other disease causing agent. Any disease pathophysiology involves specific biological pathways, which are targeted with the help of diagnostic tests. Diagnostic images of the particular molecule then identifies presence of the specific mutation or receptors (in case of cancer), which can be targeted with the help of therapeutic agents. This approach avoids trial and error treatment and could be used to offer patient specific treatment at the right time. Accurate dose calibration and precisely targeted approach could highly be useful in management of chronic diseases such as cancer.

For instance, neuro endocrine tumors can be diagnosed to assess extent of disease via PET-CT (Positron Emission Tomography – Computer Tomography) using Ga-68 DOTATOC (a radioactive positron emitter). Ga-68 targets somatostatin receptor (SSTR2) on the tumor cell membrane, and is injected through vein, which travels and binds to the SSTR2 indication the presence of tumor on PET scan. Furthermore, Ga-68 can be replaced by a therapeutic agent to target the tumor.

However, improperly defined regulations for these tests coupled with inadequate reimbursement facilities are expected to hamper growth of the global theranostics market over the forecast period.

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/theranostics-market-2043

Global Theranostics Market Regional Insights:-

North America is expected to witness significant growth in the global theranostics market over the forecast period. Presence of leading manufacturers, collaborations, robust research, and development activities, and increasing adoption of companion diagnostics is expected to support global theranostics market growth over the forecast period. Biocartis Group NV and Amgen, Inc. partnered to develop companion diagnostic test for Amgen's drug Vectibix (panitumumab) in 2017. For instance, Genome Canada launched a national initiative for clinical implementation of precision health in June 2018, which would ultimately impact global theranostics market growth over the forecast period.

Asia Pacific theranostics market is expected to witness significant growth over the forecast period, owing to collaborations in the region by global organizations and increasing awareness regarding companion diagnostics. For instance, Qiagen collaborated with Japan based clinical lab testing company, SRL, Inc. for introduction of new companion diagnostics with new drug approvals in August 2018.

Key players of Global Theranostics Market:-

Key players operating in the global theranostics market include Thermo Fisher Scientific, Inc., Beckman Coulter, Inc., Focus Diagnostics, AmeriPath, Inc., Illumina, Inc., F.Hoffmann LA-Roche Ltd., Qiagen NV, Myriad Genetics, Inc., Agilent Technologies, Abbott Laboratories, Foundation Medicine, Inc., and Oxford Cancer Biomarkers, Ltd.

Key Development:-

In 2018, THERADIAG, a company specialized in vitro diagnostics and theranostics entered into partnership agreement with Biogaran to supply its Lisa Tracker kits for Biogaran biosimilar monitoring.

In 2018, Novartis AG, entered into an agreement with Endocyte, a US-based Biopharmaceutical Company which develops targeted therapeutics for cancer treatment.

In 2018 RadioMedix Inc. and AREVA Med LLC, announced the Phase 1 trial for AlphaMedixTM in patients with somatostatin receptor positive neuroendocrine tumors in the U.S. AlphaMedixTM is composed of a somatostatin (SST) analogue radiolabeled with 212Pb, an isotope used for Targeted Alpha-emitter Therapy (TAT).

In 2016, avant diagnostics and Amarantus Diagnostics have signed a letter of intent to acquire theranostics health, a protein analysis service provider.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/2043

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

mailto:[email protected]

U.S. Office:

Name: Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US : +1-206-701-6702

UK : +44-020-8133-4027

JAPAN : +050-5539-1737

#Theranostics Market Growth #Theranostics Market

0 notes

healtcare · 3 years

Text

Global Haematology and Flow Cytometry Market

Global Haematology and Flow Cytometry Market is expected to reach $XX Mn by 2026 from $XX Mn in 2019, at a CAGR of 8.5% during forecast period.

Global Haematology and Flow Cytometry Market Overview:

Hematology is a medical specialty that deals with the study and treatment of blood. This is concerned with the diagnosis, study, treatment, and prevention of blood diseases. Flow cytometry is an analytical tool that is used in the measurement and analysis of several physical characteristics of cells or particles suspended in a fluid using a laser beam. The method helps to subclassify cell types to decide on the best treatment plan.

Global Haematology and Flow Cytometry Market Dynamics:

Rising global incidence and prevalence of chronic diseases like blood cancer is the major driving factor for the market growth. According to the National Cancer Institute in 2018, it was being estimated that 60,300 new leukemia cases are diagnosed and the deaths are around 24,470 cases in the United States. The increasing number of HIV cases globally is an important driver for the flow cytometry market. This is because the flow cytometry technique has its direct application in HIV diagnosis. According To UNAIDS in 2017, 31.1-43.9 million people globally are living with HIV by out of which 1.8 million are newly affected with HIV. Flow cytometry uses light scattering to determine the identity of cells. Increasing adoption of flow cytometry techniques in research and academia and growing initiatives in the field of immunology and Immuno-oncology researches are expected to propel the growth of the global flow cytometry market. Growth in stem cell research and the development of high-throughput flow cytometry technologies are likely to add new opportunities for this market in the coming years. Increasing regulatory approval and the introduction of technologically advanced flow cytometry solutions are expected to facilitate market growth over the forecast period. For instance, in June 2020, Sysmex Corporation launched the XF-1600 flow cytometer for laboratories, in North America. A significant restraint on the flow cytometry market is the availability of cheaper and better alternatives. ELISA (enzyme-linked immunosorbent assay) and radioimmunoassay are two of these alternatives. Although flow cytometry, ELISA, and radioimmunoassay are all methods for detecting "problem cells" in a community of cells, ELISA and radioimmunoassay are less expensive and easier to use. Along with this, the dearth of skilled technicians for managing such advanced technology is expected to restrain the market growth. The report has profiled twenty key players in the market from different regions. However, report has considered all market leaders, followers and new entrants with investors while analyzing the market and estimation the size of the same. Increasing R&D activities in each region are different and focus is given on the regional impact on the cost, availability of advanced technology are analyzed and report has come up with recommendations for future hot spot in APAC region.

Global Haematology and Flow Cytometry Market Segment Analysis:

The Global Haematology and Flow Cytometry Market is segment on the basis of Product, Technology and End-Users. Based on Product, the flow cytometry instruments segment is expected to dominate the global market. The segment is further classified into cell analyzers and cell sorters. It held a market share of 25% in 2020. This high share is attributed to new advancements in technology and the introduction of novel cytometers by key players. The high price of these instruments is also contributing toward the high revenue generation in this segment. Along with this, reagents and consumables also held a prominent share in 2020. Owing to their increased adoption in diagnostics and research the segment is expected to register lucrative growth over the forecast period. The large share of this segment is mainly attributed to the growing research activities to develop and prove the efficacy of various assays and kits, and the commercialization of high-quality and application-specific consumables, reagents, and assays. Based on technology, the cell-based flow cytometry segment held the largest market share of 76% in 2020. The highest share is due to an increase in demand for early diagnosis and increased understanding of the related benefits of cell-based assays. In addition, advances in cell-based assay technology, such as innovations in tools, labels, affinity reagents, software, and algorithms, are expected to accelerate adoption in the coming years. To know about the Research Methodology :- Request Free Sample Report

Global Haematology and Flow Cytometry Market Regional Insights:

North America dominated the global market in 2020. The region dominated the global market in 2020 by holding a market share of 39.1%. This dominance is attributed due to the United States' high healthcare spending, well-developed healthcare system, and widespread adoption of technologically advanced flow cytometry solutions. In addition, the established pharmaceutical industry, as well as extensive research activities by research universities and pharmaceutical companies has generated huge demand for flow cytometry solutions for research universities and pharmaceutical companies have created a huge demand for flow cytometry solutions for research needs. APAC region is projected to exhibit highest CAGR during forecast period. This high growth can be attributed to the extensive growth in the pharmaceutical and biotechnology industries of emerging economies, such as China and India. The lucrative growth exhibited by this region is also an outcome of continuous government support for the establishment of the pharmaceutical industry in emerging countries. The report also helps in understanding Global Haematology and Flow Cytometrys Market dynamics, structure by analyzing the market segments and project the Global Haematology and Flow Cytometrys Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Haematology and Flow Cytometrys Market make the report investor’s guide.

Global Haematology and Flow Cytometry Market, key developments:

• In September 2018, the U.S. FDA awarded a grant of ~$18 million over a period of four years for 12 new clinical trials. These clinical trials are aimed at developing products for patients with rare diseases (including primary sclerosing cholangitis, stargardt disease, Cushing disease, acute myeloid leukemia, and graft versus host disease, among others). • In March 2017, Cytek Biosciences Inc., a manufacturer and supplier of flow cytometry products and services launched its DxP Athena flow cytometry system. The system is compact, powerful, easy-to-use cell analyzer that are typically only found in conventional instruments that come with a much higher price tag. The DxP Athena makes the benefits of flow cytometry which are more readily available to larger number of researchers by its compact size. • In 2016, the Global Clinical Trials Fund (U.K.) launched a dedicated fund with an upper limit of $662,185 to support clinical trials across the world related to the testing of new experimental drugs and existing drugs developed for dementia.

Global Haematology and Flow Cytometry Market Scope: Inquire before buying

Global Haematology and Flow Cytometry Market, by Region:

• North America • Europe • South America • MEA • APAC

Global Haematology and Flow Cytometry Market, Key players:

• Becton, Dickinson and Company • Beckman Coulter, Inc. • Bio-Rad Laboratories, Inc. • Thermo Fisher Scientific, Inc. • Merck KGaA • Sysmex Partec GmbH • Luminex Corporation • Miltenyi Biotec GmbH • Sony Biotechnology • Abbott • Agilent Technologies • CellaVision • Horiba • Nihon Kohden • Ortho-Clinical Diagnostics • Roche • Siemens Healthineers • Sysmex • Miltenyi Biotec • Apogee Flow Systems Ltd.

#Haematology #Flow Cytometry #Haematology and Flow Cytometry

0 notes

rdagade · 3 years

Text

Global Haematology and Flow Cytometry Market

is expected to reach $XX Mn by 2026 from $XX Mn in 2019, at a CAGR of 8.5% during forecast period.

Global Haematology and Flow Cytometry Market Overview:

Global Haematology and Flow Cytometry Market Dynamics:

Increasing adoption of flow cytometry techniques in research and academia and growing initiatives in the field of immunology and Immuno-oncology researches are expected to propel the growth of the global flow cytometry market. Growth in stem cell research and the development of high-throughput flow cytometry technologies are likely to add new opportunities for this market in the coming years. Increasing regulatory approval and the introduction of technologically advanced flow cytometry solutions are expected to facilitate market growth over the forecast period. For instance, in June 2020, Sysmex Corporation launched the XF-1600 flow cytometer for laboratories, in North America. A significant restraint on the flow cytometry market is the availability of cheaper and better alternatives.

ELISA (enzyme-linked immunosorbent assay) and radioimmunoassay are two of these alternatives. Although flow cytometry, ELISA, and radioimmunoassay are all methods for detecting "problem cells" in a community of cells, ELISA and radioimmunoassay are less expensive and easier to use. Along with this, the dearth of skilled technicians for managing such advanced technology is expected to restrain the market growth.

The report has profiled twenty key players in the market from different regions. However, report has considered all market leaders, followers and new entrants with investors while analyzing the market and estimation the size of the same. Increasing R&D activities in each region are different and focus is given on the regional impact on the cost, availability of advanced technology are analyzed and report has come up with recommendations for future hot spot in APAC region.

Global Haematology and Flow Cytometry Market Segment Analysis:

Based on technology, the cell-based flow cytometry segment held the largest market share of 76% in 2020. The highest share is due to an increase in demand for early diagnosis and increased understanding of the related benefits of cell-based assays. In addition, advances in cell-based assay technology, such as innovations in tools, labels, affinity reagents, software, and algorithms, are expected to accelerate adoption in the coming years.

To know about the Research Methodology :-

Request Free Sample Report

Global Haematology and Flow Cytometry Market Regional Insights:

This high growth can be attributed to the extensive growth in the pharmaceutical and biotechnology industries of emerging economies, such as China and India. The lucrative growth exhibited by this region is also an outcome of continuous government support for the establishment of the pharmaceutical industry in emerging countries. The report also helps in understanding Global Haematology and Flow Cytometrys Market dynamics, structure by analyzing the market segments and project the Global Haematology and Flow Cytometrys Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Haematology and Flow Cytometrys Market make the report investor’s guide.

Global Haematology and Flow Cytometry Market, key developments:

For more information visit@ https://www.maximizemarketresearch.com/market-report/global-haematology-and-flow-cytometry-market/98749/

Global Haematology and Flow Cytometry Market Scope: Inquire before buying

Global Haematology and Flow Cytometry Market, by Region:

• North America • Europe • South America • MEA • APAC

Global Haematology and Flow Cytometry Market, Key players:

This report submitted by Maximize market Research Company

Customization of the report:

Maximize Market Research provides free personalized of reports as per your demand. This report can be personalized to meet your requirements. Get in touch with us and our sales team will guarantee provide you to get a report that suits your necessities.

About Maximize Market Research:

Maximize Market Research provides B2B and B2C research on 20,000 high growth emerging opportunities & technologies as well as threats to the companies across the Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Lumawant Godage

Organization Address: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: [email protected]

Address: Omkar Heights, Sinhagad Road, Manik Baug, Vadgaon Bk,Pune, Maharashtra 411051, India.

Contact: +919607195908

#Global Haematology and Flow Cytometry Market

0 notes

cool-akashy-maximize · 3 years

Text

Global Leukemia Therapeutics Market : Industry Analysis and Forecast (2019-2027)

Global Leukemia Therapeutics Market was valued at US$ 11.32 Bn in 2019 and is expected to reach US$ 19.2 Bn by 2027, at a CAGR of 7.84 % during the forecast period.

The report includes an analysis of the impact of COVID-19 lockdown on the revenue of market leaders, followers, and disruptors. Since the lockdown was implemented differently in various regions and countries; the impact of the same is also seen differently by regions and segments. The report has covered the current short-term and long-term impact on the market, and it would help the decision-makers to prepare the outline and strategies for companies by region. Global Leukemia Therapeutics MarketGlobal Leukemia Therapeutics Market Dynamics:

Increased prevalence of cancer especially blood cancer across the globe is leading to increasing demand for effective treatments, which is the driving factor for market growth. Increase in expenditure on the development of novel treatment and developing health infrastructure is further driving the market growth. Additionally, the growth in survival rate and minimum side effects of novel treatment such as stem cell therapy, bone marrow transplant has open new avenues for market growth. Also, increased exposer to chemical mutation, changing dietary habits, and the living style of the population is further pushing the market growth.

The lack of early diagnosis and awareness among the public are leading challenges in the market for leukemia therapeutics. Furthermore, redefining the drug lifecycle roadmap is a major challenge for drug innovators. However, breakthrough therapy designations and accelerated approvals granted by regulatory bodies like the FDA would offer lucrative market opportunities for the drug innovators. Segment Analysis of the Global Leukemia Therapeutics Market:

Based on treatment type, chemotherapy led the segment in 2019. Because of its ability to kill cancerous cells or inhibiting their proliferation and maintain a normal level of lymphocytes of chemotherapy, is driving the market growth. Similarly, the increased survival rate of the patients treated with chemotherapy is again fueling its demand.

On the basis of the type of leukemia, acute lymphocytic leukemia is dominating the segment and has accounted for maximum market share. Owing to the rising condition of cancerous cells, acute leukemia is driving the segment growth. Increasing smoking habits, exposure to chemicals, radiation, and cases with other blood-related disorders are again driving the segment growth. Regional Insights of the Global Leukemia Therapeutics Market:

In terms of region, North America followed by Europe dominates the global leukemia therapeutics market owing to the growing incidence of cancer and increasing aging population. The APAC is expected to show a high growth rate because of the increasing incidence of cancer. China and India are expected to be the fastest-growing leukemia markets in the Asia Pacific region. Some of the key driving forces for the leukemia therapeutic market in emerging economies are increasing R&D investment, a large pool of patients, and growing government funding.

Key developments in leukemia therapeutics market: In February 2018, Sanofi announced to discard the mid-stage exertion on ALL therapy for the anti-CD38 antibody isatuximab. Also, Erytech Pharma broadened the scope of eryaspase (GRASPA) growth for solid tumors further clinical studies in triple-negative breast cancer.

The objective of the report is to present a comprehensive assessment of the market and contain thoughtful insights, facts, historical data, industry-validated market data and projections with a suitable set of assumptions and methodology. The report also helps in understanding Global Leukemia Therapeutics Market dynamics, structure by identifying and analyzing the market segments and project the global market size. Further, the report also focuses on the competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence. Scope of the Global Leukemia Therapeutics Market Report:

Global Leukemia Therapeutics Market, by Type of Leukemia

• Chronic Myeloid Leukemia • Chronic Lymphocytic Leukemia • Acute Lymphocytic Leukemia • Acute Myeloid Leukemia

Global Leukemia Therapeutics Market, by Treatment Type

• Targeted Drugs & Immunotherapy • Chemotherapy

Global Leukemia Therapeutics Market, by Molecule Type

• Small Molecules • Biologics

Global Leukemia Therapeutics Market, by Mode of Administration

• Oral Mode • Injectable Mode

Global Leukemia Therapeutics Market, by Gender

• Males • Females

Global Leukemia Therapeutics Market, by Region

• North America • Europe • Asia Pacific • Middle East and Africa • South America Key Players Operating in the Global Leukemia Therapeutics Market:

• Novartis AG • AbbVie • Bristol-Myers Squibb • Hoffmann-La Roche • Sanofi • Pfizer • Amgen • Gilead Sciences • Takeda • Celgene • AbARIAD Pharmaceuticals, Inc. • F. Hoffmann-La Roche Ltd. • Genzyme Corporation • GlaxoSmithKline plc. • Teva Pharmaceuticals • Allergan, • AstraZeneca, • F. Hoffmann-La Roche Ltd, • Pfizer Inc., • Merck KGaA, Merck & Co., Inc.,

For More Information Visit @: This Report Is Submitted By : Maximize Market Research Company Customization of the report: Maximize Market Research provides free personalized of reports as per your demand. This report can be personalized to meet your requirements. Get in touch with us and our sales team will guarantee provide you to get a report that suits your necessities.

About Maximize Market Research: Maximize Market Research provides B2B and B2C research on 20,000 high growth emerging opportunities & technologies as well as threats to the companies across the Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

0 notes

kenresearch1 · 11 months

Text

Top 3 US Pharmaceutical Companies and Their Strategies in US Acute Myeloid Leukemia Market

Buy Now

US Acute Myeloid Leukemia Market is growing due to advancement in treatment approaches, increase healthcare costs and expenditure, growing investments in Research and Development, and a constant growth in population.

Story Outline

Pfizer Inc.- An American multinational company with the highest annual revenue of around 100 billion US$ in 2022 in the drug market. The company has made significant contributions to the US Acute Myeloid Leukemia Market through a sophisticated, robust, agile manufacturing infrastructure and investment in research and development.

Brystol Myers Squibb- One of the largest American pharmaceutical companies which consistently ranks on the Fortune 500 list of the largest US corporations. The company’s mission is to discover, develop, and deliver innovative medicines that help patients as well as prevail over serious diseases.

Novartis AG- The company with the fourth-largest revenue in the drug market which is focused to deliver high-value medicine that alleviate society’s greatest disease burdens through technology leadership in R&D and novel access approaches.

The US Acute Myeloid Leukemia Market is expected to grow at CAGR of 10.5% in the forecast period 2022-2028.

The Acute Myeloid Leukemia Market of US is driving growth at an amazing level. This surge is a result of advancement in treatment approaches, increases healthcare costs and expenditure, growing investments in Research and Development, and a constant growth in population.

Various pharmaceutical companies are actively shaping this growing market with their strategies and innovations.

This article provides an in-depth look at major pharmaceutical companies with their strategies and innovations.

1.Pfizer Inc.

Click here: To know more about Pfizer Inc.

Pfizer Inc. is an American multinational pharmaceutical company and headquartered at The Spiral in Manhattan, New York City. The company has made significant contributions to the US Acute Myeloid Leukemia Market through a sophisticated, robust, agile manufacturing infrastructure and investing in research and development.

The company employs more than 30,000 employees worldwide, have 35+ manufacturing sites, 300+ external suppliers, and have reached more than 180 countries. Pfizer tops the list of drug market by achieving a revenue of approx. 100 billion USD in 2022.

Pfizer has made significant contributions to the US acute Myeloid Leukemia Market. Some notable contributions are, in April 2017, the development and approval of a targeted therapy called “Rydapt”, which is an oral kinase inhibitor that targets multiple enzymes, including FLt3, which is often mutated in AML patients. The drug was approved by FDA in April 2017 for use in combination with Chemotherapy.

Furthermore, MYLOTARG is approved in combination with daunorubicin and cytarabine for the treatment of patients aged 15 and above with previously untreated, de novo, CD33-positive acute myeloid leukemia (AML), except Acute Promyelocytic Leukemia (APL).

The company’s purpose is “Breakthroughs that change patients' lives—fuels everything we do and reflects our passion for building on our legacy as one of the greatest contributors of good to the world.

The company says that its purpose ensures that its patients remain at the center of all that they do. They live with their purpose by sourcing the best science in the world; partnering with others in the healthcare system to improve access to their medicines.

Pfizer believes in growing partnerships with innovators to initiate forward great science and continually seek new partners that are actively researching bold scientific ideas. In December 2022, Pfizer announced its collaboration with Gero’s machine learning technology platform to discover potential therapeutic targets for fibrotic using large-scale human-based data.

Pfizer’s continuous clinical trials and collaboration with healthcare institutions and research organizations has majorly contributed in advancing Acute Myeloid Leukemia Market and the development of novel treatment strategies.

2.Bristol Myers Squibb

Click here: To Download a Sample Report

The Bristol Myers Squibb Company, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. BMS is one of the world’s largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest US corporations.

The company employs more than 34,000 across more than 86 locations worldwide. The company’s revenue in 2022 was approximately 46 bn USD.

Their mission is to discover, develop, and deliver innovative medicines that help patients as well as prevail over serious diseases. Bristol believes in the power of science to address some most challenging diseases of today's world.

Bristol Myers is majorly known for its contributions to oncology, and immunology and its involvement in Acute Myeloid Leukemia Market with its broader focus on cancer treatments.

The significant development of BMS can be noted from June 2021, Bristol Myers Squibb received approval from European Commission for Onureg, a Frontline oral maintenance therapy for adult patients with acute Myeloid Leukemia who achieved their first complete remission (CR) or CR with incomplete blood count recovery following intensive induction chemotherapy. Onureg is expected to increase sales and product revenue, thereby increasing the US Acute Myeloid Leukemia Market growth.

Furthermore, the strategic cooperation between Evotec and Bristol Myers Squibb has grown in order to create a pipeline for programs addressing more neurological illnesses. In order to find altering therapies for a variety of neurodegenerative disorders, the firms started working together in 2016. The eight-year extension is intended to strengthen the strategic partnership even more.

3.Novartis AG

Click Here : To Download a Custom Report

Novartis AG is a healthcare company that majorly focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical and eye care products. Novartis offers generic medicines and biosimilars through Sandoz. The company conducts its research through The Novartis Institute for Biomedical Research (NIBR).

Novartis is one of the largest pharmaceutical companies in the world and the fourth largest by revenue in 2022, which was approx. 50.500 billion USD.

The company is functioning in more than 150 locations with around 1,10,000 employees working worldwide.

Novartis's strategy as a focused medicines company is to deliver high-value medicine that alleviates society’s greatest disease burdens through technology leadership in R&D an novel access approaches.

Novartis contribution to Acute Myeloid Leukemia Market includes, FDA approval of Novartis Scemblix (asciminib), with novel mechanism of action for the treatment of Leukemia in October,2021.

Furthermore, through their open approach Novartis is focusing on new technologies to develop next generation therapeutics. Currently, Novartis is working with Orionis Bioscience to find new targets at a genome-wide scale.

By combining development and drug discovery with innovation, they aim to achieve tenuous targets and to launch novel small molecule therapy for Acute Myeloid Leukemia patients more quickly. Thus driving a steered growth for the US Acute Myeloid Leukemia Market.

0 notes

cool-cillian-murphy · 3 years

Text

Asparaginase Market - A Story of Very Rapid Development

Latest released the research study on Global Asparaginase Market, offers a detailed overview of the factors influencing the global business scope. Asparaginase Market research report shows the latest market insights with upcoming trends and breakdown of the products and services. The report provides key statistics on the market status, size, share, growth factors of the Asparaginase. The study covers emerging player’s data, including: competitive situation, sales, revenue and global market share of top manufacturers are Porton Biopharma (England), Jazz Pharmaceuticals (Ireland),Takeda (Japan),ERYTECH Pharma (France),Qianhong Bio-pharma (China),Mingxing Pharma (China),Medac GmbH (Germany),Kyowa Hakko Kirin (Japan),Alize Pharma (France),Guangzhou Baiyuan Shanmingxing Pharmaceutical (China),.

Free Sample Report + All Related Graphs & Charts @ : https://www.advancemarketanalytics.com/sample-report/6507-global-and-united-states-asparaginase-market Keep yourself up-to-date with latest market trends and changing dynamics due to COVID Impact and Economic Slowdown globally. Maintain a competitive edge by sizing up with available business opportunity in Global Asparaginase Market various segments and emerging territory.

Asparaginase Market Overview Asparaginase is a microbial product derived from Escherichia coli or from Erwinia chrysanthemi. Asparaginase is a white crystalline powder which contains the enzyme L-asparagine amidohydrolase derived from Escherichia. L-asparaginase has been reported to interface with the interpretation of thyroid function tests. It contains fungi from extreme environments which lead to the development of new chemotherapeutic treatment methods that have fewer side- effects than others. The general trade names for l-asparaginase in the United States are Elspar and Kidrolase. Market Drivers Growing Number of Cancer Patients in the United States

Increase Number Patients with Acute Lymphocytic Leukemia

Market Trend High Adoption to Treat Childhood Cancer Treatments

Increase Demand for Human Brain Function and In Ammonia Physiology

Restraints Increasing Cost of the Asparaginase Drugs Is Hamper the Growth of the Market Challenges Increasing Number of Side Effects Such As Fever, Vomits, Allergic Reaction and Others The Global Asparaginase Market segments and Market Data Break Down are illuminated below: by Type (E. Coli Asparaginase, Erwinia Asparaginase, Pegylated Asparaginase), Application (Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia), Distribution Channel (Pharmacies, Convenience Store, Online Sales, Other) Region Included are: North America, Europe, Asia Pacific, Oceania, South America, Middle East & Africa

Country Level Break-Up: United States, Canada, Mexico, Brazil, Argentina, Colombia, Chile, South Africa, Nigeria, Tunisia, Morocco, Germany, United Kingdom (UK), the Netherlands, Spain, Italy, Belgium, Austria, Turkey, Russia, France, Poland, Israel, United Arab Emirates, Qatar, Saudi Arabia, China, Japan, Taiwan, South Korea, Singapore, India, Australia and New Zealand etc. Enquire for customization in Report @: https://www.advancemarketanalytics.com/enquiry-before-buy/6507-global-and-united-states-asparaginase-market Strategic Points Covered in Table of Content of Global Asparaginase Market:

Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the Asparaginase market

Chapter 2: Exclusive Summary – the basic information of the Asparaginase Market.

Chapter 3: Displaying the Market Dynamics- Drivers, Trends and Challenges & Opportunities of the Asparaginase

Chapter 4: Presenting the Asparaginase Market Factor Analysis, Post COVID Impact Analysis, Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.

Chapter 5: Displaying the by Type, End User and Region/Country 2015-2020

Chapter 6: Evaluating the leading manufacturers of the Asparaginase market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile

Chapter 7: To evaluate the market by segments, by countries and by Manufacturers/Company with revenue share and sales by key countries in these various regions (2021-2026)

Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source Finally, Asparaginase Market is a valuable source of guidance for individuals and companies in their decision framework. Data Sources & Methodology The primary sources involves the industry experts from the Global Asparaginase Market including the management organizations, processing organizations, analytics service providers of the industry’s value chain. All primary sources were interviewed to gather and authenticate qualitative & quantitative information and determine the future prospects. In the extensive primary research process undertaken for this study, the primary sources – Postal Surveys, telephone, Online & Face-to-Face Survey were considered to obtain and verify both qualitative and quantitative aspects of this research study. When it comes to secondary sources Company's Annual reports, press Releases, Websites, Investor Presentation, Conference Call transcripts, Webinar, Journals, Regulators, National Customs and Industry Associations were given primary weight-age. For Early Buyers | Get Up to 20% Discount on This Premium Report: https://www.advancemarketanalytics.com/request-discount/6507-global-and-united-states-asparaginase-market What benefits does AMA research studies provides?

· Latest industry influencing trends and development scenario

· Open up New Markets

· To Seize powerful market opportunities

· Key decision in planning and to further expand market share

· Identify Key Business Segments, Market proposition & Gap Analysis

· Assisting in allocating marketing investments

Definitively, this report will give you an unmistakable perspective on every single reality of the market without a need to allude to some other research report or an information source. Our report will give all of you the realities about the past, present, and eventual fate of the concerned Market.

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia. About Author:

Advance Market Analytics is Global leaders of Market Research Industry provides the quantified B2B research to Fortune 500 companies on high growth emerging opportunities which will impact more than 80% of worldwide companies' revenues.

Our Analyst is tracking high growth study with detailed statistical and in-depth analysis of market trends & dynamics that provide a complete overview of the industry. We follow an extensive research methodology coupled with critical insights related industry factors and market forces to generate the best value for our clients. We Provides reliable primary and secondary data sources, our analysts and consultants derive informative and usable data suited for our clients business needs. The research study enable clients to meet varied market objectives a from global footprint expansion to supply chain optimization and from competitor profiling to M&As. Contact Us:

Craig Francis (PR & Marketing Manager) AMA Research & Media LLP Unit No. 429, Parsonage Road Edison, NJ New Jersey USA – 08837 Phone: +1 (206) 317 1218 [email protected] Connect with us at https://www.linkedin.com/company/advance-market-analytics https://www.facebook.com/AMA-Research-Media-LLP-344722399585916 https://twitter.com/amareport

0 notes

fostermarketarch · 3 years

Text

Nanopharmaceuticals Market Comprehensive Analysis And Vendor Landscape 2027

The global Nanopharmaceuticals market was valued at US$ xx million in the year 2019. The market is estimated to be valued at US$ xx million in the year 2020, and is expected to reach US$ xx million by the year 2027, with an estimated CAGR of xx% during the forecast period (2021-2027). The research study also includes exhaustive information about market dynamics such as drivers, restraints, opportunities, technological advancements, future trends, supply chain analysis, patent landscape, pricing analysis, regulatory and reimbursement framework for precise market estimations and forecasts.

Additionally, the business intelligence study encompasses the COVID-19 scenario as follows:

· Long-Term, Mid-Term, and Short-Term Impact of COVID-19

· Pre- and Post-COVID-19 Scenario

· Disruptions in the Supply Chain

Get Free PDF Brochure Of This Report @ https://www.fostermarketresearch.com/product/industry/10/160/Pdf%20Brochure/

Competitive Insights

Leading and emerging companies of the global Nanopharmaceuticalsmarket were identified based on their current offerings. Further, the Nanopharmaceuticals industry is one of the most competitive industries, with the leading players actively competing against each other to gain a greater share in the industry. Some of the major companies in the Nanopharmaceuticals market are: BlueWillow Biologics, EnColl Corporation, EyePoint Pharmaceuticals, Lena Nanoceutics Ltd., NanoSpectra biosciences Inc., Nanobiotix, Starpharma Holdings Ltd., Selecta Biosciences, Cristal Therapeutics, Celgene Inc., Aquanova AG, Nanology LLC, and Others

The competitive landscape of the Nanopharmaceuticals industry exhibits an inclination towards emerging strategies including product launches, partnerships, collaborations and contracts, acquisitions, funding, and other developments to achieve the objectives faster.

Our reports fill up the gaps and provide you with all the detailed analysis of competitive companies involving:

· Analyzing competitive strategies and techniques

· Competitive positioning of key players

· PORTER’s and SWOT analysis for competitive risk analysis

· Competitive Share Analysis

· Financial analysis of players to determine their withstand capacity

· Analyzing their sales path and product study

For More Information Of This Report @ https://www.fostermarketresearch.com/product/industry/10/160/

Key Segments Covered in the global Nanopharmaceuticals market report are:

· By Carrier Type: (Liposomes, Polymer, Nanocrystals, Protein, Inorganic, and Others)

· By Application: (Oncological diseases, Neurological Diseases, Orthopedic Disorders, Cardiovascular Diseases, Infectious Diseases, Urological Diseases, Others)

Regional Coverage:

The global Nanopharmaceuticals market segregates into five regions including North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. North America followed by Europe held the major share of the global market (in terms of value) in 2020. However, Asia-Pacific region exhibit highest CAGR (%) during the forecast period (2021-2027). Our research study further sub-divides regions into countries as follows:

· North America - the U.S. and Canada

· Europe - Germany, the U.K., France, Spain, Italy, Russia, and Rest-of-Europe

· Asia-Pacific - China, India, Japan, South Korea, Australia, ASEAN, and Rest-of-Asia-Pacific

· Latin America - Mexico, Brazil, and Rest-of-Latin America

· Middle East and Africa - Gulf Cooperation Council (GCC) Countries, South Africa, Israel, and Rest-of-Middle East and Africa

Market Dynamics:

Technological advancements in the healthcare industry have always played a crucial role in development of Nanopharmaceuticals market. The major factors driving the growth of this market are government and private funding to support the development of regenerative medicine, rising prevalence of chronic diseases and genetic disorders, increase in the global healthcare expenditure, and rapid growth in the aging population. In August 2017, the company, Jazz Pharmaceuticals received FDA approval for Vyxeos. Vyxeos is basically used for the treatment of acute myeloid leukemia. However, factors such as less solubility of nano-pharmaceuticals and toxicity issues, may hinder the growth of the nanopharmaceutical market.

Buy Now This Business Strategic Report To Improve Your Profits @ https://www.fostermarketresearch.com/product/buy/10/160/

About Foster Market Research:

Foster Market Research is a global market intelligence and advisory firm engaged in providing data-driven research extract from rigorous analysis, to the clients to make critical business decisions and execute them successfully. Foster connects over various distribution channels and numerous markets for great understanding of the trends and market to deliver our clients with accurate data.

Our focus is on providing market research that delivers a positive impact on your business. We work continuously to provide our clients with the most accurate analytics data and research reports without any delay so as to improve their business strategies and provide them with rich customer experience.

1701 Royal Lane,

#1306, Dallas

Tx-75229

Phone: +1 469 4981929

Email: [email protected]

0 notes

leonfrancisblog · 4 years

Text

Hemato Oncology Testing Market Global Trends, Growth, Opportunities, Market Size Forecast to 2027|Major Competitors Abbott Laboratories, QIAGEN, Thermo Fisher Scientific Inc., Illumina, Inc., Bio-Rad Laboratories, Inc., MolecularMD, ArcherDx, Inc

Hemato oncology testing market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to hemato oncology testing market This hemato oncology testing market report provides details of market share, new developments, product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief our team will help you create a revenue impact solution to achieve your desired goal.

Increasing cases of hematologic cancer and growing awareness about the advanced treatment therapies among population will drive the market growth. Rising cases of myeloma cancers and lymphoma will also affect the market positively. Leukemia patients are constantly keeping track on the status of minimal residual disease which is also expected to affect the market positively. Favourable reimbursement policy on the hemato oncology testing products will also enhance the market growth. On the other hand, rising collaboration between manufacturer, increasing conferences on personalized medicines, and growing demand for advanced treatment options will also create new opportunities for the hemato oncology testing market in the forecast period of 2020- 2027.

Global Hemato Oncology Testing Market By Product & Services (Services, Assay Kits), Cancer Type (Leukemia, Lymphoma, Other Cancers), Technology (PCR, IHS, NGS, Cytogenetics, Other), End- Users (Clinical Laboratories, Hospitals, Academic & Research Institutes, Others), Country (U.S., Canada, Mexico, Brazil, Argentina, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa), Market Share Forecast to 2027Hemato Oncology Testing market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to growat a CAGR of 14.10% in the above-mentioned forecast period. Increasing cases of leukemia and increasing demand for personalized medicines will create new opportunities for this market in the forecast period of 2020- 2027.Hemotology is that route of medicine which deals with the treatment, causes, and other problems associated with the blood. On the other hand, oncology is connected with the study of the treatment, diagnosis, and other problem associated with cancer. Hematolo-oncology is the method used to treat diseases and blood disorders and cancers.

Get An Sample Request on Get an Sample Request on Global Hemato Oncology Testing Market: https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-hemato-oncology-testing-market

Hemato Oncology Testing Market Country Level Analysis:

Hemato oncology testing market is analyzed and market size insights and trends are provided product & services, cancer type, technology and end use as referenced above.

The country section of the hemato oncology testing market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data. The countries covered in the hemato oncology testing market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific in the Asia-Pacific, Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa as a part of Middle East and Africa, Brazil, Argentina and Rest of South America as part of South America. North America dominates the hemato oncology testing market due to favourable reimbursement policy for hemato oncology testing products while Asia-Pacific is expected to grow at the highest growth rate in the forecast period 2020 to 2027 due to increasing patient population.

Healthcare Infrastructure growth Installed base and New Technology Penetration:

Hemato oncology testing market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment’s, installed base of different kind of products for hemato oncology testing market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the hemato oncology testing market. The data is available for historic period 2010 to 2018.

Global Hemato Oncology Testing Market Scope and Market Size:

Hemato oncology testing market is segmented of the basis of product & services, cancer type, technology and end use. The growth amongst these segments will help you analyze meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Based on product & services, hemato oncology testing market is segmented into services, and assay kits.

On the basis of cancer type, the hemato oncology testing market is classified into leukemia, lymphoma, and other cancers. Leukemia is further divided into acute myeloid leukemia, acute lymphocytic leukemia, and other leukemia. Lymphoma is segmented into non-Hodgkin lymphoma and Hodgkin lymphoma. The hemato oncology testing market is also segmented on the basis of technology as PCR, IHS, NGS, cytogenetic, and other. The global hemato oncology testing market has also been segmented based on the end use into clinical laboratories, hospitals, academic & research institutes, and others.

The major players covered in the hemato oncology testing market report are F. Hoffmann-La Roche Ltd, Abbott Laboratories, QIAGEN, Thermo Fisher Scientific Inc., Illumina, Inc., Bio-Rad Laboratories, Inc., MolecularMD, ArcherDx, Inc., ARUP Laboratories., Invivoscribe, Inc., CORE Diagnostics, Genoptix, Inc., GenPath, NeoGenomics Laboratories, Inc., Siemens AG, among other players domestic and global. Market Share data is available for Global, North America, Europe, Asia-Pacific, Middle East and Africa and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Get Table of Content https://www.databridgemarketresearch.com/toc/?dbmr=global-hemato-oncology-testing-market

Reasons for buying this Global Hemato Oncology Testing Market:

Laser Capture Global Hemato Oncology Testing Market aids in understanding the crucial product segments and their perspective.

Initial graphics and exemplified that a SWOT evaluation of large sections supplied from the Laser Capture Global Hemato Oncology Testing Market.

Even the Laser Capture Global Hemato Oncology Testing Market economy provides pin line evaluation of changing competition dynamics and retains you facing opponents.

This report provides a more rapid standpoint on various driving facets or controlling Medical Robotic System promote advantage.

This worldwide Locomotive report provides a pinpoint test for shifting dynamics that are competitive.

The key questions answered in this report:

What will be the Market Size and Growth Rate in the forecast year?

What is the Key Factors driving Laser Global Hemato Oncology Testing Market?

What are the Risks and Challenges in front of the market?

Who are the Key Vendors in Global Hemato Oncology Testing Market?

What are the Trending Factors influencing the market shares?

What is the Key Outcomes of Porter’s five forces model

Access Full Report https://www.databridgemarketresearch.com/reports/global-hemato-oncology-testing-market

Browse Related Report:

North America Metabolic Testing Market

Pharmaceutical Equipment Testing Market

Sterility Testing Market

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818

Email: [email protected]

#Market by Type Market Development Market Forecast Market Size Future Innovation Market Future Trends Market Share Market Demand Market Growt

0 notes

top-market-research · 4 years

Text

Acute Myeloid Leukemia Therapeutics Market Share, Industry Analysis, Forecast and Global Research Report

The in-depth study on the Acute Myeloid Leukemia Therapeutics Market covers a comprehensive analysis of the historical data, present and emerging market trends, technological advancements, and the overall market scenario. The report titled Global Acute Myeloid Leukemia Therapeutics Market published by Reports and Data analyze the current market scene, market share, growth rate, future trends, market drivers, opportunities, and challenges, risks and entry barriers. The report includes a comprehensive assessment of the positive and negative factors influencing the growth and trends of the market.

The global Acute Myeloid Leukemia Therapeutics market is forecasted to grow at a rate of 13.1% from USD 1.46 billion in 2019 to USD 3.56 billion in 2027.

The report considers COVID-19 as a key market contributor. The report describes in detail the effect of the COVID-19 pandemic on the major segments of the Acute Myeloid Leukemia Therapeutics Market sector. The pandemic has affected the Acute Myeloid Leukemia Therapeutics Market sector dynamically and the report covers the changes in demands and trends in the market. The report studies threats and challenges the industry players will have to face due to the changes induced by COVID-19 pandemic. Furthermore, the report provides a detailed description of the COVID-19 impact on the overall growth of the market.

Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/3354

The report is an all-inclusive document containing a thorough assessment of the top market players operating in the industry and controlling a significant share of the market. A breakdown analysis of the competitive landscape comprising of expansion tactics and strategic alliances adopted by the companies are offered in the report. The report covers a detailed assessment of mergers & acquisitions, product launches, partnerships & agreements, joint ventures, and collaborations, among others happening between the prominent industry players.

Key Players Operating in the Market and Profiled in the Report are:

Ambit Biosciences Corporation, Cephalon, Clavis Pharma, Eisai, Genzyme Corporation, Sunesis Pharmaceuticals, Takeda Pharmaceuticals, Amgen, Celgene, and Sanofi have been profiled in the report. They are the major manufacturers of the Regimen.

Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/3354

The reports presents encyclopedic company profiles of the leading participants of the Acute Myeloid Leukemia Therapeutics Market industry to allow the reader to gain a better understanding of the competitive landscape to help in formulating better decisions and investment strategies. It also covers SWOT analysis and Porter’s Five Forces analysis to impart a better understanding of the key players operating in the market.

Additionally, the report consists a detailed analysis of the segmentation of the Acute Myeloid Leukemia Therapeutics Market based on product types and end-use/application offered in the Acute Myeloid Leukemia Therapeutics Market. The report an exhaustive summary of the product and application landscape of the industry along with details about the segmented expected to show significant growth in the upcoming years.

Based on the product type, the Acute Myeloid Leukemia Therapeutics Market is segmented into

Chemotherapy

Radiation therapy

Stem Cell Transplant

Targeted Therapy

Based on the application spectrum, the Acute Myeloid Leukemia Therapeutics Market is segmented into

Hospital

Retails Drug Stores

Ambulatory Care Centers

Clinics

To know more about the report, visit @ https://www.reportsanddata.com/report-detail/acute-myeloid-leukemia-therapeutics-market

The report provides an extensive detailing of the market share and size of the Acute Myeloid Leukemia Therapeutics Market industry in the key geographical regions. Based on the regional breakdown, the market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

In-depth regional analysis covers:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, France, Rest of EU)

Asia Pacific (India, Japan, China, South Korea, Australia, Rest of APAC)

Latin America (Chile, Brazil, Argentina, Rest of Latin America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)

Request customization of the report @ https://www.reportsanddata.com/request-customization-form/3354

Browse Related Reports –

Photomedicine Market Growth

Cervical Cancer Diagnostic Market

Photomedicine Market Drivers

Bioinformatics Market Manufacturers

Blood Culture Tests Market Revenue

Thank you for reading our report. For further query or inquiry, kindly get in touch with us and our team will ensure your requirements for the reports are met.

#Leukemia Therapeutics Market

0 notes

akashthings · 4 years

Text

Global Leukemia Market Demand and Supply Trends 2024

Summary – A Global Leukemia Market - Size, Trends, Competitive Analysis, Market Share and Forecasts (2018-2025)-” has been featured on WiseGuyReports.

Leukemia is one of the most deliberating cancer types which substantially contributes to the global disease burden and mortality rates. Leukemia is a type of blood cancer. It typically originates in the bone marrow and results in the abnormality in leucocytes. The major types of leukemias include – acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and chronic myeloid leukemia (CML).

ALSOREAD:https://wiseguyreports.wordpress.com/2020/07/14/leukemia-2020-global-market-analysis-top-key-players-trends-share-industry-size-segmentation-opportunities-forecast-to-2026/

Prevalence of leukemia is quite high globally. According to GLOBOCAN 2020, leukemia ranked the 11th most common cancer type affecting the population globally which an incidence of 0.35 million in 2012 and its incidence is expected to rise to 0.41 million by 2020. Increasing cancer prevalence, improving treatment rates, the rise in standards of healthcare infrastructure especially in merging nations, the emergence of combination therapeutic options for treatment of leukemia types and the scope of drug re-positioning formed the impetus for the market growth in recent years and will also propel the market in the forecast period. (2018-2025)

The global market for leukemia was worth $XX billion in 2017 and is forecasted to reach $XX billion by 2025, growing at a CAGR of XX%.

Global Leukemia Market – Market Dynamics

The demand for leukemia therapeutics will expand at a notable rate in the foreseeable future primarily driven by the product approval of repositioned drugs, the concept of application for expanded indication approvals for the existing drugs and advent of novel therapeutics; high practice of off-label prescriptions, increase in prevalence population; high R&D investments and rise in healthcare standards especially on emerging countries. The market is anticipated to be restrained by high costs associated with drug development. adverse side-effects associated with chemotherapeutic options and inadequate access to healthcare in rural regions of emerging countries. However, favorable public initiatives and the emergence of innovative therapeutics are anticipated to create promising growth opportunities for the market players in the leukemia market across the globe.

Overall the key market drivers include –

Increase in Prevalence of Leukemia Sub-types

Robust Pipeline with Potential Late-Stage Molecules

Favorable Special Regulatory Designations for Drugs

High R&D Investments For Drug Discovery

Increase in Diagnosis and Treatment Seeking Population

Overall the key market restraints include –

Complex Disease Prognosis

Adverse Effects of Therapeutic Options

The dearth of Healthcare Professionals in Emerging Countries

Inadequate Reimbursement and Treatment Access

Market Trends and Opportunities

High focus on Combination Therapies and Drug-Repositioning

The emergence of Targeted Therapies

Global Leukemia Market – Segment Analysis (By Disease Type)

Based on disease type the global market for Leukemia are broadly segmented- namely acute lymphocytic leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, and chronic myeloid leukemia.

The market currently is dominated by chronic lymphocytic leukemia therapeutics. In the forecast period, the market the market for acute lymphocytic leukemia and chronic myeloid leukemia are anticipated to contribute a notable share of the overall leukemia therapeutics.

Global Leukemia Market – Geographical Analysis

The global market for leukemia therapeutics is segmented into North America, Europe, Asia Pacific, South America and the Middle East and Africa. North America contributed the highest market followed by Europe in 2017. High disease awareness, favorable reimbursement, high healthcare access, advanced healthcare infrastructure, high disease prevalence and favorable government policies and initiatives are key factors for substantial market size in these regions.

In terms of growth rate, APAC is anticipated to post highest growth rate in forecast period owing to the development of the healthcare infrastructure in especially contributed by China and India. Rising investments for R&D activities are projected to encourage the growth of the leukemia therapeutics market in APAC region. In addition, increasing healthcare expenditures, rising prevalence of leukemia are also anticipated to fuel the market’s growth in the forecast period.

Global Leukemia Market

Global Leukemia Market – Competitive Analysis

The competitive landscape for Leukemia therapeutics is concentrated with a limited number of key vendors contributing to substantial market share. The remaining minor share is contributed by multiple international as well as local vendors manufacturing low-cost generic chemotherapeutic drugs.

The key vendors are continually focusing to strengthen its market competitiveness by the high focus of R&D, innovation of novel combination therapeutics. Companies are also increasingly focusing on patient assistance programs and drug repositioning to gain the competitive edge and improve market entrenchment.

Some of the major companies operating in the global leukemia market are – AbbVie, Novartis, Pfizer, Bristol-Myers Squibb Company, Genzyme, Celgene, GlaxoSmithKline, Cephalon, Eisai and Teva Pharmaceuticals.

Scope of the Report

The report covers the factors impacting the market, Porter 5 Forces, Market Share Analysis, by-therapy analysis, by disease analysis, and company profiles. Global leukemia market is segmented based on the disease type as acute lymphocytic leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, and chronic myeloid leukemia. Based on therapy type market is categorized as – targeted/immune therapies and chemotherapeutics. Based on geography the market is segmented into – North America, South America, Europe, Asia Pacific and the Middle East and Africa.

The report profiles the following companies – AbbVie, Novartis, Pfizer, Bristol-Myers Squibb Company, Genzyme, Celgene, Glaxosmithkline, Cephalon, Eisai and Teva Pharmaceuticals, Ambit Biosciences, Genmab A/S and Talon Therapeutics/

Why Purchase the report?

Visualize the composition of the leukemia market across each indication, in terms of therapy type and disease type, highlighting the key commercial assets and players.

Identify commercial opportunities in leukemia by analyzing trends and co-development deals.

This is the most comprehensive study on leukemia market to date.

Excel data sheet with thousands of data points of the leukemia market – level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key leukemia drugs of all major market players.

Target Audience

Raw Material Suppliers/ Buyers

Product Suppliers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturer

...FOR MORE DETAILS: https://www.wiseguyreports.com/reports/3792271-global-leukemia-market-size-trends-competitive-analysis-market

About Us:

Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.

NORAH TRENT

[email protected]

Ph: +162-825-80070 (US)

Ph: +44 203 500 2763 (UK)

#Leukemia Market Demand

0 notes

cindy893 · 4 years

Text

Hemato Oncology Testing Market Business Insights and Development Analysis from 2020-2026 | F. Hoffmann-La Roche, Abbott Laboratories, Thermo Fisher Scientific

This report added to the broad database of confirmed research titled Hemato Oncology Testing by manufacturer, region, type and application, forecast up to 2026. Hemato Oncology Testing is proposed to feature direct documentation of all the best executions in the business. The Hemato Oncology Testing report contains a top to bottom investigation of present and future market patterns, division, mechanical chances and the future market situation, considering the estimate years 2020 to 2026. It contains critical subtleties on the key players in the Hemato Oncology Testing advertise just as development situated practices, that they typically use. The report looks at various development drivers and constraining elements. The key conjecture data by type and application with deals and income from 2020 to 2026 is remembered for Hemato Oncology Testing report.

Request Sample Report at: http://www.marketresearchglobe.com/request-sample/1313500

This particular and mastery arranged industry explore Keyword report examines the specialized and business viewpoint of the industry. The Keyword report breaks down and announces the recorded and current patterns investigation of the industry. In this manner prescribes the anticipated patterns foreseen to be seen in the Keyword report advertise during the up and coming years.

Major Key players of the Global Hemato Oncology Testing Market-

F. Hoffmann-La Roche

Abbott Laboratories

Thermo Fisher Scientific

QIAGEN N.V.

Bio-Rad Laboratories

Illumina

MolecularMD

Invivoscribe

Asuragen

Adaptive Biotechnologies

ArcherDx

ARUP Laboratories

Types are divided into:

Leukemia Testing

Acute Myeloid Testing

Multiple Myeloma Testing

Other

Applications are divided into:

Clinical Laboratories

Hospitals

The Keyword report highlights the most recent market trends. Keyword report unveils vulnerabilities that may emerge because of changes in business activities or presentation of another item in the market. This Keyword market report is generated with the combination of best industry insight, practical solutions, talent solutions and latest technology.

Significant Regions covered in this report:

North America, China,Europe, Japan, Southeast Asia, India, Central & South America

Check Discount for Report: http://www.marketresearchglobe.com/check-discount/1313500

Which are the Key Questions to buy the Hemato Oncology Testing report?

What will be analyzing center capabilities and pieces of the overall industry of key players in the Hemato Oncology Testing and thoroughly profiling them?

What are the Unveiling significant possibilities and openings accessible in the Hemato Oncology Testing advertise?

What will be researching the market based future possibilities, development patterns, and Hemato Oncology Testing elements?

What are the market size of driving fragments and sub-sections of the Hemato Oncology Testing?

What are the Hemato Oncology Testing market openings and methods adopted and seen by the players?

Enquire Additional Concerning the Report at: http://www.marketresearchglobe.com/send-an-enquiry/1313500

Customization of this Report: This Hemato Oncology Testing report could be customized to the customer's requirements. Please contact our sales professional ([email protected]), we will ensure you obtain the report which works for your needs.

0 notes